Abstract
Several lines of evidence suggest that the dopaminergic nervous system contributes to methamphetamine (METH) dependence, and there is increasing evidence of antagonistic interactions between dopamine and adenosine receptors in METH abusers. We therefore hypothesized that variations in the A1 adenosine receptor (ADORA1) gene modify genetic susceptibility to METH dependence/psychosis. In this study, we identified 7 single nucleotide polymorphisms (SNPs) in exons and exon-intron boundaries of the ADORA1 gene in a Japanese population. A total of 171 patients and 229 controls were used for an association analysis between these SNPs and METH dependence/psychosis. No significant differences were observed in either the genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. In the clinical feature analyses, no significant associations were observed among latency of psychosis, prognosis of psychosis, and spontaneous relapse. These results suggest that the ADORA1 gene variants may make little or no contribution to vulnerability to METH dependence/psychosis.
Keywords: Single nucleotide polymorphism, SNP, variation, human, Japanese, MAP, abuse, dopamine, adenosinergic function, dopaminergic system
Current Neuropharmacology
Title: Association Analysis of the Adenosine A1 Receptor Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis
Volume: 9 Issue: 1
Author(s): > Kobayashi, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Mitsuhiko Yamada, Yoshimoto Sekine, Naohisa Uchimura, Masaomi Iyo, Norio Ozaki, Masanari Itokawa and Ichiro Sora
Affiliation:
Keywords: Single nucleotide polymorphism, SNP, variation, human, Japanese, MAP, abuse, dopamine, adenosinergic function, dopaminergic system
Abstract: Several lines of evidence suggest that the dopaminergic nervous system contributes to methamphetamine (METH) dependence, and there is increasing evidence of antagonistic interactions between dopamine and adenosine receptors in METH abusers. We therefore hypothesized that variations in the A1 adenosine receptor (ADORA1) gene modify genetic susceptibility to METH dependence/psychosis. In this study, we identified 7 single nucleotide polymorphisms (SNPs) in exons and exon-intron boundaries of the ADORA1 gene in a Japanese population. A total of 171 patients and 229 controls were used for an association analysis between these SNPs and METH dependence/psychosis. No significant differences were observed in either the genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. In the clinical feature analyses, no significant associations were observed among latency of psychosis, prognosis of psychosis, and spontaneous relapse. These results suggest that the ADORA1 gene variants may make little or no contribution to vulnerability to METH dependence/psychosis.
Export Options
About this article
Cite this article as:
Kobayashi >, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari and Sora Ichiro, Association Analysis of the Adenosine A1 Receptor Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016958
DOI https://dx.doi.org/10.2174/157015911795016958 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Current Advances in Delivery of Biotherapeutics Across the Blood-Brain Barrier
Current Drug Discovery Technologies Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Cellular, Molecular and Non-Pharmacological Therapeutic Advances for the Treatment of Parkinson's Disease: Separating Hope from Hype
Current Gene Therapy Genetic Variation of Chromosome 1q42: Etiologic Mechanism of Congenital Disorders of Neuronal Migration and Synaptogenesis
Current Psychiatry Reviews Dogs with Cognitive Dysfunction Syndrome: A Natural Model of Alzheimer’s Disease
Current Alzheimer Research Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders The Effect of Cannabis on Perception of Time: A Critical Review
Current Pharmaceutical Design Effects of Nicotine During Pregnancy: Human and Experimental Evidence
Current Neuropharmacology Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery Drug-Related Decrease in Neuropsychological Functions of Abstinent Drug Users
Current Drug Abuse Reviews Modulators of Pain: Bv8 and Prokineticins
Current Neuropharmacology Nitric Oxide Control of Proliferation in Nerve Cells and in Tumor Cells of Nervous Origin
Current Pharmaceutical Design Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry Resting-State Networks in Schizophrenia
Current Topics in Medicinal Chemistry The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued)